Targeting SARS-CoV2 spike protein receptor binding domain by therapeutic antibodies
Fecha
2020Autor
Hussain, Arif
Hasan, Anwarul
Nejadi Babadaei, Mohammad Mahdi
Haj Bloukh, Samir
Chowdhury, Muhammad E.H.
Sharifi, Majid
Haghighat, Setareh
Falahati, Mojtaba
Documentos PDF
Resumen
As the number of people infected with the newly identified 2019 novel coronavirus (SARSCoV2) is continuously increasing every day, development of potential therapeutic platforms is
vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARSCoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV
monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs
targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive
development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the
discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site.
Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230,
80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of
interaction of RBD and different mAbs were explained and it was suggested that one of the SARSCoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARSCoV2 S-protein RBD. Finally, some ongoing challenges and future perspective for rapid and
sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In
conclusion, it may be proposed that this review may pave the way for recognition of RBD and
different mAbs to develop potential therapeutic ESV.
Palabras clave
Corona virus; Spike protein; Receptor binding domain; Antibodies; Epitope-specific vaccines (ESV)Enlace al recurso
https://doi.org/10.1016/j.biopha.2020.110559Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.